Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00074204
Status:
COMPLETED
Last Update Posted:
2010-08-16
First Post:
2003-12-10
Brief Title:
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Sponsor:
Case Comprehensive Cancer Center
Organization:
Case Comprehensive Cancer Center
Study Overview
Official Title:
A Phase III Study of Delayed vs Immediate Second-Line Therapy With Docetaxel After Gemcitabine Carboplatin in Advanced Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as gemcitabine carboplatin and docetaxel use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells It is not yet known which treatment regimen is more effective for stage IIIB or stage IV non-small cell lung cancer
PURPOSE Randomized phase III trial to compare the effectiveness of gemcitabine and carboplatin followed immediately by docetaxel with that of giving delayed docetaxel in treating patients who have stage IIIB or stage IV non-small cell lung cancer
PURPOSE Randomized phase III trial to compare the effectiveness of gemcitabine and carboplatin followed immediately by docetaxel with that of giving delayed docetaxel in treating patients who have stage IIIB or stage IV non-small cell lung cancer
Detailed Description:
OBJECTIVES
Primary
Compare the overall survival of patients with stage IIIB or IV non-small cell lung cancer treated with gemcitabine and carboplatin followed by immediate vs delayed docetaxel
Secondary
Compare the response rate and time to progression in patients treated with these regimens
Compare the toxicity of these regimens in these patients
Compare the quality of life of patients treated with these regimens
OUTLINE This is a randomized study Patients are stratified according to ECOG performance status 0 or 1 vs 2
All patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1 Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity
Patients with stable or responding disease proceed to docetaxel therapy Patients are randomized to 1 of 2 treatment arms
Arm I immediate docetaxel Patients receive immediate docetaxel IV over 1 hour on day 1
Arm II delayed docetaxel Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1
In both arms treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity
Quality of life QOL is assessed at baseline at restaging after completion of gemcitabine and carboplatin before courses 2-6 of docetaxel and then at 1 and 3 months after study treatment
NOTE For patients randomized to delayed docetaxel QOL is assessed every 3 weeks until first disease progression and then before courses 2-6 of docetaxel
Patients are followed monthly for 3 months every 2 months for 6 months and then every 3 months thereafter
PROJECTED ACCRUAL A total of 550 patients 275 per treatment arm will be accrued for this study
Primary
Compare the overall survival of patients with stage IIIB or IV non-small cell lung cancer treated with gemcitabine and carboplatin followed by immediate vs delayed docetaxel
Secondary
Compare the response rate and time to progression in patients treated with these regimens
Compare the toxicity of these regimens in these patients
Compare the quality of life of patients treated with these regimens
OUTLINE This is a randomized study Patients are stratified according to ECOG performance status 0 or 1 vs 2
All patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1 Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity
Patients with stable or responding disease proceed to docetaxel therapy Patients are randomized to 1 of 2 treatment arms
Arm I immediate docetaxel Patients receive immediate docetaxel IV over 1 hour on day 1
Arm II delayed docetaxel Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1
In both arms treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity
Quality of life QOL is assessed at baseline at restaging after completion of gemcitabine and carboplatin before courses 2-6 of docetaxel and then at 1 and 3 months after study treatment
NOTE For patients randomized to delayed docetaxel QOL is assessed every 3 weeks until first disease progression and then before courses 2-6 of docetaxel
Patients are followed monthly for 3 months every 2 months for 6 months and then every 3 months thereafter
PROJECTED ACCRUAL A total of 550 patients 275 per treatment arm will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LILLY-B9E-US-S245 | Other Identifier | Case Comprehensive Cancer Center | httpsreporternihgovquickSearchP30CA043703 |
| P30CA043703 | NIH | None | None |
| CASE-CWRU-LILY-1503 | OTHER | None | None |